This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Entrareg, ADL 8-2698, alvimopan
Description: Entereg is a peripherally-acting mu opioid receptor antagonist (PAMOR) designed to block the negative effects of opioids, likemorphine or codeine, on the gastrointestinal system without interfering with the analgesic effects on the central nervous system.
Shire and Lilly
Adolor paid Roberts Laboratories, which merged with Shire Pharmaceuticals, a total of $600,000 through June 30, 2001 for the exclusive worldwide license to Entereg. Adolor's license agreement with Roberts requires the company to make payments to Roberts if and when two milestones are achieved. Roberts licensed the rights to Entereg from Eli Lilly. Under an agreement with Eli Lilly, Adolor will make a milestone payment to Eli Lilly if and when Adolor receives approval from the United States Food and Drug Administration, or FDA, to sell Entereg. Adolor will be required to pay royalties to Eli Lilly and Roberts on any sales of Entereg.
GlaxoSmithKline and Adolor
In April 2002, Adolor entered into a collaboration agreement with Glaxo for the exclusive worldwide development and commercialization of Entereg for certain indications. Adolor is responsible for development of acute indications, such as POI, and Glaxo is responsible for development of...See full deal structure in Biomedtracker
Partners: Shire Pharmaceuticals Group PLC Eli Lilly & Company
Pink Sheet Entereg FDA Reviewers
Pink Sheet Entereg Clinical Development
Pink Sheet Adolor at work on Entereg NDA
Additional information available to subscribers only: